Few targets have undergone as dramatic a turnaround as KRAS, one of the most commonly mutated proteins in cancer. For decades KRAS seemed intractable to direct attacks, a teflon target with nowhere ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...
The enzyme KRas has become a popular cancer target for drugmakers in the last decade, with many companies developing small molecules that inhibit one or multiple KRas mutants. Now, scientists are ...
AstraZeneca’s business development team has landed another asset in its new favorite hunting grounds. Partnering with a Chinese biotech once again, the Anglo-Swedish drugmaker has secured a spot in ...
A total of 137 patients (60 with non–small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related ...
An alternate strategy to target individual KRAS mutations is the development of Proteolysis Targeting Chimeras (PROTACs). This class of medications allows for targeted degradation of mutant KRAS ...
Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...
KRAS has long been one of cancer's most elusive enemies. But we're now seeing real momentum—from understanding how KRAS mutations reshape tumor biology to designing drugs that can outsmart them. What ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback